Glucagon-like Peptide 1-Based Drugs and Pancreatic Safety

被引：1
作者：
Brodovicz, Kimberly G. [1 ]
Engel, Samuel S. [1 ]
Thornberry, Nancy A. [1 ]
机构：
[1] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA
来源：
JAMA INTERNAL MEDICINE | 2013年 / 173卷 / 19期
关键词：
SITAGLIPTIN;
D O I：
10.1001/jamainternmed.2013.8138
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1842 / +
页数：2
相关论文
共 50 条
[41]   Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice [J].
Steven, Sebastian ;
Jurk, Kerstin ;
Kopp, Maximilian ;
Kroeller-Schoen, Swenja ;
Mikhed, Yuliya ;
Schwierczek, Kathrin ;
Roohani, Siyer ;
Kashani, Fatemeh ;
Oelze, Matthias ;
Klein, Thomas ;
Tokalov, Sergey ;
Danckwardt, Sven ;
Strand, Susanne ;
Wenzel, Philip ;
Muenzel, Thomas ;
Daiber, Andreas .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (12) :1620-1632
[42]   Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio [J].
Kaneko, Masayuki ;
Narukawa, Mamoru .
ANNALS OF PHARMACOTHERAPY, 2018, 52 (07) :632-638
[43]   Prevention of Myocardial Stunning During Percutaneous Coronary Interventions Novel Insights From Pre-Treatment With Glucagon-Like Peptide-1 [J].
Brott, Brigitta C. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (02) :302-304
[44]   Nateglinide Stimulates Glucagon-Like Peptide-1 Release by Human Intestinal L Cells via a KATP Channel-Independent Mechanism [J].
Kitahara, Yoshiro ;
Miura, Kyoko ;
Yasuda, Reiko ;
Kawanabe, Haruka ;
Ogawa, Shimpei ;
Eto, Yuzuru .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (05) :671-676
[45]   Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials [J].
Madsbad, Sten ;
Krarup, Thure ;
Deacon, Carolyn F. ;
Holst, Jens J. .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (04) :491-499
[46]   Sitagliptin protects the cognition function of the Alzheimer's disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings [J].
Dong, Qing ;
Teng, Shuai-Wen ;
Wang, Yue ;
Qin, Feng ;
Li, Yue ;
Ai, Lu-Lu ;
Yu, Hui .
NEUROSCIENCE LETTERS, 2019, 696 :184-190
[47]   Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes [J].
Xie, Cong ;
Wang, Xuyi ;
Jones, Karen L. ;
Horowitz, Michael ;
Sun, Zilin ;
Little, Tanya J. ;
Rayner, Christopher K. ;
Wu, Tongzhi .
DIABETES OBESITY & METABOLISM, 2020, 22 (03) :383-392
[48]   Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes [J].
Kishimori, Takefumi ;
Kato, Takao ;
Wada, Atsuyuki ;
Tani, Akira ;
Yamaji, Ryosuke ;
Koike, Jumpei ;
Iwasaki, Yoshihiro ;
Matsumoto, Takehiro ;
Yagi, Takafumi ;
Okada, Masaharu .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (04)
[49]   Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis [J].
Yuan, Daniel ;
Sharma, Harman ;
Krishnan, Anirudh ;
Vangaveti, Venkat N. ;
Malabu, Usman H. .
DIABETES OBESITY & METABOLISM, 2022, 24 (09) :1869-1881
[50]   Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes [J].
Mari, A. ;
Del Prato, S. ;
Ludvik, B. ;
Milicevic, Z. ;
de la Pena, A. ;
Shurzinske, L. ;
Karanikas, C. A. ;
Pechtner, V. .
DIABETES OBESITY & METABOLISM, 2016, 18 (08) :834-839
12345